Guardian Wealth Advisors LLC NC Boosts Stake in Boston Scientific Co. (NYSE:BSX)

Guardian Wealth Advisors LLC NC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 8.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,598 shares of the medical equipment provider’s stock after buying an additional 205 shares during the quarter. Guardian Wealth Advisors LLC NC’s holdings in Boston Scientific were worth $232,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Gen Wealth Partners Inc purchased a new position in Boston Scientific in the 4th quarter valued at about $72,000. Gotham Asset Management LLC lifted its stake in Boston Scientific by 43.7% in the 4th quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider’s stock worth $1,021,000 after purchasing an additional 3,475 shares in the last quarter. Focus Partners Wealth lifted its stake in Boston Scientific by 156.5% in the 4th quarter. Focus Partners Wealth now owns 379,253 shares of the medical equipment provider’s stock worth $33,881,000 after purchasing an additional 231,371 shares in the last quarter. Fullerton Fund Management Co Ltd. lifted its stake in Boston Scientific by 52.3% in the 4th quarter. Fullerton Fund Management Co Ltd. now owns 1,553,156 shares of the medical equipment provider’s stock worth $138,728,000 after purchasing an additional 533,346 shares in the last quarter. Finally, Ellevest Inc. lifted its stake in Boston Scientific by 4.9% in the 4th quarter. Ellevest Inc. now owns 13,923 shares of the medical equipment provider’s stock worth $1,244,000 after purchasing an additional 650 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on BSX. Needham & Company LLC raised their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, April 24th. Erste Group Bank raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday. Royal Bank of Canada raised their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, April 24th. Barclays raised their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Finally, Citigroup raised their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $114.52.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig sold 12,000 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the transaction, the director now owns 24,398 shares in the company, valued at $2,573,501.04. The trade was a 32.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the business’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now owns 18,705 shares of the company’s stock, valued at approximately $1,955,420.70. This trade represents a 19.64% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 300,497 shares of company stock worth $31,056,815 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.4%

Shares of NYSE BSX opened at $102.87 on Monday. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $98.68 and a 200-day simple moving average of $96.07. The stock has a market capitalization of $152.19 billion, a PE ratio of 82.30, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.56 earnings per share. On average, equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.